Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Similar articles for PubMed (Select 22714958)


The intestinal bioavailability of vaccenic acid and activation of peroxisome proliferator-activated receptor-α and -γ in a rodent model of dyslipidemia and the metabolic syndrome.

Wang Y, Jacome-Sosa MM, Ruth MR, Lu Y, Shen J, Reaney MJ, Scott SL, Dugan ME, Anderson HD, Field CJ, Proctor SD, Vine DF.

Mol Nutr Food Res. 2012 Aug;56(8):1234-46. doi: 10.1002/mnfr.201100517. Epub 2012 Jun 20.


Trans-11 vaccenic acid reduces hepatic lipogenesis and chylomicron secretion in JCR:LA-cp rats.

Wang Y, Jacome-Sosa MM, Ruth MR, Goruk SD, Reaney MJ, Glimm DR, Wright DC, Vine DF, Field CJ, Proctor SD.

J Nutr. 2009 Nov;139(11):2049-54. doi: 10.3945/jn.109.109488. Epub 2009 Sep 16.


Trans-11 vaccenic acid dietary supplementation induces hypolipidemic effects in JCR:LA-cp rats.

Wang Y, Lu J, Ruth MR, Goruk SD, Reaney MJ, Glimm DR, Vine DF, Field CJ, Proctor SD.

J Nutr. 2008 Nov;138(11):2117-22. doi: 10.3945/jn.108.091009.


Increased hypolipidemic benefits of cis-9, trans-11 conjugated linoleic acid in combination with trans-11 vaccenic acid in a rodent model of the metabolic syndrome, the JCR:LA-cp rat.

Jacome-Sosa MM, Lu J, Wang Y, Ruth MR, Wright DC, Reaney MJ, Shen J, Field CJ, Vine DF, Proctor SD.

Nutr Metab (Lond). 2010 Jul 16;7:60. doi: 10.1186/1743-7075-7-60.


PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.

Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, Kim A, Yeon JE.

J Gastroenterol Hepatol. 2008 Jan;23(1):102-9. doi: 10.1111/j.1440-1746.2006.04819.x. Erratum in: J Gastroenterol Hepatol. 2009 May;24(5):932. J Gastroenterol Hepatol. 2009 Jul;24(7):1310.


Flax oil-mediated activation of PPAR-γ correlates with reduction of hepatic lipid accumulation in obese spontaneously hypertensive/NDmcr-cp rats, a model of the metabolic syndrome.

Chechi K, Yasui N, Ikeda K, Yamori Y, K Cheema S.

Br J Nutr. 2010 Nov;104(9):1313-21. doi: 10.1017/S0007114510002187. Epub 2010 Jun 15.


Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.

Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R.

Mediators Inflamm. 2013;2013:549627. doi: 10.1155/2013/549627. Epub 2013 May 27. Review.


Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.

Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D.

Neuropharmacology. 2005 Jun;48(8):1147-53. Epub 2005 Apr 21.


Vaccenic acid favourably alters immune function in obese JCR:LA-cp rats.

Blewett HJ, Gerdung CA, Ruth MR, Proctor SD, Field CJ.

Br J Nutr. 2009 Aug;102(4):526-36. doi: 10.1017/S0007114509231722. Epub 2009 Feb 16.


Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC.

J Gastroenterol Hepatol. 2012 Feb;27(2):341-50. doi: 10.1111/j.1440-1746.2011.06939.x.


Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.

Oakes ND, Thalén P, Hultstrand T, Jacinto S, Camejo G, Wallin B, Ljung B.

Am J Physiol Regul Integr Comp Physiol. 2005 Oct;289(4):R938-46.


A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.

Jeong HW, Lee JW, Kim WS, Choe SS, Kim KH, Park HS, Shin HJ, Lee GY, Shin D, Lee H, Lee JH, Choi EB, Lee HK, Chung H, Park SB, Park KS, Kim HS, Ro S, Kim JB.

Diabetes. 2011 Feb;60(2):496-506. doi: 10.2337/db09-1145.


Rice protein isolate improves lipid and glucose homeostasis in rats fed high fat/high cholesterol diets.

Ronis MJ, Badeaux J, Chen Y, Badger TM.

Exp Biol Med (Maywood). 2010 Sep;235(9):1102-13. doi: 10.1258/ebm.2010.010039. Epub 2010 Jul 28.


Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure.

Mori Y, Hirano T, Nagashima M, Shiraishi Y, Fukui T, Adachi M.

Metabolism. 2007 Dec;56(12):1714-8.


Differential effects of in vivo PPAR alpha and gamma activation on fatty acid transport proteins expression and lipid content in rat liver.

Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, Gorski J.

J Physiol Pharmacol. 2009 Mar;60(1):99-106.


The natural carotenoid astaxanthin, a PPAR-α agonist and PPAR-γ antagonist, reduces hepatic lipid accumulation by rewiring the transcriptome in lipid-loaded hepatocytes.

Jia Y, Kim JY, Jun HJ, Kim SJ, Lee JH, Hoang MH, Hwang KY, Um SJ, Chang HI, Lee SJ.

Mol Nutr Food Res. 2012 Jun;56(6):878-88. doi: 10.1002/mnfr.201100798.


Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.

Zhao X, Xue J, Wang XL, Zhang Y, Deng M, Xie ML.

Int Immunopharmacol. 2014 Sep;22(1):176-81. doi: 10.1016/j.intimp.2014.06.032. Epub 2014 Jun 30.


Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome.

Jacome-Sosa MM, Borthwick F, Mangat R, Uwiera R, Reaney MJ, Shen J, Quiroga AD, Jacobs RL, Lehner R, Proctor SD.

J Nutr Biochem. 2014 Jul;25(7):692-701. doi: 10.1016/j.jnutbio.2014.02.011. Epub 2014 Mar 18.


Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling.

Ronis MJ, Chen Y, Badeaux J, Badger TM.

J Nutr. 2009 Aug;139(8):1431-8. doi: 10.3945/jn.109.107029. Epub 2009 Jun 10.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk